STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test Double-Duty immunotherapy to hold back aggressive head & neck cancer
Disease control Recruiting nowThis study is for adults whose nasopharyngeal cancer (a type of head and neck cancer linked to the Epstein-Barr virus) has returned or spread. After initial chemotherapy and immunotherapy, patients who are stable are randomly assigned to continue with standard immunotherapy alone…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Cholesterol drug may boost cancer treatment in new trial
Disease control Recruiting nowThis study is testing whether adding the common cholesterol-lowering drug lovastatin to the immunotherapy drug pembrolizumab can better control head and neck cancer that has returned or spread. Researchers believe lovastatin may make cancer cells more vulnerable to the immune sys…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for Tough-to-Treat throat cancer: three drugs vs. two
Disease control Recruiting nowThis study is for people with advanced nasopharyngeal cancer (a type of throat cancer) that has spread or returned after standard treatments. It will test if adding a pill called cabozantinib to two immunotherapy drugs (nivolumab and ipilimumab) works better than the two immunoth…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for young cancer patients: testing a powerful drug combo
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug called nivolumab to standard chemotherapy works better for young people (up to age 21) newly diagnosed with nasopharyngeal cancer. The goal is to see if this combination is safe and can better control the cancer before pa…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Doctors test custom vaccine to fight returning head and neck cancer
Disease control Recruiting nowThis early-stage study is testing a personalized vaccine made from a patient's own tumor cells. It aims to see if the vaccine, given alone or with an immunotherapy drug (pembrolizumab), is safe and can help the immune system fight advanced head and neck cancer that has returned o…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Scientists probe why cancer patients skip crucial throat exercises
Knowledge-focused Recruiting nowThis study aims to understand why some head and neck cancer patients follow, and others skip, prescribed swallowing exercises after radiation therapy. Researchers will collect blood samples and ask patients to fill out questionnaires to see if factors like mood, pain, immune syst…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC